Personalized medicine and antiplatelet therapy: ready for prime time?
Verstuyft
Céline
C
Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, 339 Windermere Road, London, Ontario N6A 5A5, Canada.
Simon
Tabassome
T
Kim
Richard B
RB
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000235:genetics; D002986:Clinical Trials as Topic; D065731:Cytochrome P-450 CYP2C19; D004347:Drug Interactions; D004351:Drug Resistance; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000235:genetics; D011110:Polymorphism, Genetic; D057285:Precision Medicine; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D054328:Proton Pump Inhibitors; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19